Systemic and mucosal immune signatures of protection against SARS-CoV-2 transmission in humans.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41406942.
- Also identified by DOI 10.1016/j.xcrm.2025.102505 and PMC identifier 12765841.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Binding and neutralizing antibodies against the spike (S) protein of SARS-CoV-2 have been associated with a reduced risk of symptomatic infection. However, precise immune protection thresholds remain unclear. We aim to define systemic and mucosal antibody correlates of protection against SARS-CoV-2 infection. Our household COVID-19 cohort (the CIDS) consists of 52 families (52 index cases and 139 exposed contacts). Immunoglobulin subtyping against S of SARS-CoV-2 and HCoV-OC43 in the serum and upper respiratory tract is quantified to assess the protection provided by virus-specific pre-existing immunity. Logistic regression analyses indicate that multiple antibody isotypes are associated with reduced infection risk. Specifically, multivariable models show that systemic anti-SARS-CoV-2 S1 IgG and anti-OC43 S2 IgM independently correlate with protection. Besides, local mucosal anti-SARS-CoV-2 S IgG and HCoV-OC43 S IgA antibodies add protective potential. However, an integrated analysis reveals that systemic antibodies against SARS-CoV-2 remain the best predictor against virus infection.
Medical subject headings
- COVID-19
- SARS-CoV-2
- Antibodies, Viral
- Immunity, Mucosal